Palonosetron intravenous - Exela Pharma Sciences

Drug Profile

Palonosetron intravenous - Exela Pharma Sciences

Alternative Names: Palonosetron hydrochloride intravenous - Exela Pharma Sciences

Latest Information Update: 12 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Exela Pharma Sciences
  • Class Antiemetics; Isoquinolines; Quinuclidines; Small molecules
  • Mechanism of Action Serotonin 3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Chemotherapy-induced nausea and vomiting

Most Recent Events

  • 31 Aug 2016 Chemical structure information added
  • 22 Aug 2016 Registered for Chemotherapy induced nausea and vomiting (Prevention) in USA (IV)
  • 22 Mar 2016 FDA issues tentative approval to palonosetron (0.125 mg/ml) injection for the prevention of Chemotherapy induced nausea and vomiting (In adults) in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top